1. Home
  2. TLS vs AVIR Comparison

TLS vs AVIR Comparison

Compare TLS & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Telos Corporation

TLS

Telos Corporation

HOLD

Current Price

$4.31

Market Cap

317.1M

Sector

Technology

ML Signal

HOLD

Logo Atea Pharmaceuticals Inc.

AVIR

Atea Pharmaceuticals Inc.

HOLD

Current Price

$5.89

Market Cap

450.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TLS
AVIR
Founded
1969
2012
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
317.1M
450.9M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
TLS
AVIR
Price
$4.31
$5.89
Analyst Decision
Buy
Buy
Analyst Count
5
2
Target Price
$7.90
$8.00
AVG Volume (30 Days)
924.6K
499.0K
Earning Date
05-08-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
31.51
3.00
EPS
N/A
N/A
Revenue
$164,805,000.00
$351,367,000.00
Revenue This Year
$18.72
N/A
Revenue Next Year
$14.62
N/A
P/E Ratio
N/A
N/A
Revenue Growth
52.21
N/A
52 Week Low
$1.83
$2.46
52 Week High
$8.36
$6.45

Technical Indicators

Market Signals
Indicator
TLS
AVIR
Relative Strength Index (RSI) 49.49 61.74
Support Level $3.80 $3.33
Resistance Level $4.69 $6.45
Average True Range (ATR) 0.25 0.28
MACD 0.03 -0.04
Stochastic Oscillator 59.88 73.72

Price Performance

Historical Comparison
TLS
AVIR

About TLS Telos Corporation

Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.

About AVIR Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.

Share on Social Networks: